General
Preferred name
ERIBAXABAN
Synonyms
PD-0348292 ()
PD-348292 ()
PD-348 ()
PD 348,292 ()
292 ()
PD 348 ()
P&D ID
PD005780
CAS
536748-46-6
Tags
available
drug candidate
Drug indication
Thrombosis
Drug Status
investigational
experimental
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Eribaxaban is a Pfizer experimental anticoagulant which targets activated factor X (FXa) . It has reached Phase 2 for prevention of venous thromboembolism in knee replacement (GtoPdb)
DESCRIPTION Eribaxaban is an orally active inhibitor of coagulation factor Xa (activated factor X). It has anticoagulant activity and is used as an anticoagulant drug. It is used for the treatment and prevention of thrombotic disorders. It inhibited arterial thrombosis comparable to aspirin plus clopidogrel. It was developed by Pfizer. It was in phase II clinical trials, but has been terminated. (BOC Sciences Bioactive Compounds)
Compound Sets
7
BOC Sciences Bioactive Compounds
eribaxaban-cas-536748-46-6-item-182311
ChEMBL Drugs
CHEMBL476186
DrugBank
DB06920
DrugMAP
DMMYNKH
Guide to Pharmacology
7408
MedChem Express Bioactive Compound Library
HY-10267
ReFrame library
External IDs
20
Properties
(calculated by RDKit )
Molecular Weight
484.13
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
3.89
TPSA
92.67
Fraction CSP3
0.21
Chiral centers
2.0
Largest ring
6.0
QED
0.57
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Metabolic Enzyme/Protease
Target
Factor Xa
Solubility
Soluble in DMSO, not in water
Source data